Evidence map›Paper›PMID 31177659›Full record

Trial reportZhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology2019

[A phase II, single-arm, open-label, multicenter clinical study to evaluate the efficacy and safety of sofosbuvir combined with ribavirin in patients with genotype 2 chronic hepatitis C virus infection].

Y H Gao, G M Li, Q L Jin, Y R Zhao, Z S Jia, X R Mao, Y F Yang, J Shang, G C Wang, W Xie and 9 more

Abstract readClinical Trial, Phase IIMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Y H GaoDepartment of Hepatology, Peking University People's Hospital, Beijing 100044, China (now in Peking University International Hospital).
G M LiDepartment of Hepatology, Zhengzhou Sixth People's Hospital, Zhengzhou 450061, China.
Q L JinDepartment of Hepatobiliary and Pancreatic, Jilin University First Hospital, Changchun 130021, China.
Y R ZhaoDepartment of Infectious Disease, Xi'an Jiaotong University School of Medicine First Affiliated Hospital, Xi'an 710065, China.
Z S JiaCenter of Infectious Diseases and Liver Diseases, Fourth Military Medical University Tangdu Hospital, Xi'an 710038, China.
X R MaoDepartment of Infectious Disease, Lanzhou University First Hospital, Lanzhou 730000, China.
Y F YangDepartment of Hepatology, Nanjing Second Hospital, Nanjing 210028, China.
J ShangDepartment of Infectious Disease, Henan Provincial People's Hospital, Zhengzhou 450003, China.
G C WangDepartment of Hepatology, Dalian Sixth People's Hospital, Dalian 116001, China.
W XieCenter of Liver Disease Study, Beijing Ditan Hospital, Beijing 100015, China.
S M WuDepartment of Hepatology, Shanghai Public Health Clinical Center, Shanghai 201508, China.
M X ZhangDepartment of Traditional and Western Medical Hepatology, Shenyang Sixth People's Hospital, Shenyang 110006, China.
J L HouDepartment of Infectious Disease, Southern Medical University Southern Hospital, Guangzhou 510515, China.
D L LiDepartment of Hepatobiliary, Nanjing Military Region Fuzhou General Hospital, Fuzhou 350025, China.
Y M NanDepartment of Traditional and Western Medical hepatology, Hebei Medical University Third Hospital, Shijiazhuang 050000, China.
Y J GuanDepartment of Hepatology, Guangzhou Eighth People's Hospital, Guangzhou 510060, China.
C X ZhuNanjing Chia Tai Tianqing Co., Ltd, Nanjing 210000, China.
Y Z YuanNanjing Chia Tai Tianqing Co., Ltd, Nanjing 210000, China.
L WeiDepartment of Hepatology, Peking University People's Hospital, Beijing 100044, China (now in Beijing Tsinghua Changgung Hospital).

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Antiviral AgentsChinaDrug Therapy, CombinationGenotypeHepacivirusHepatitis C, ChronicHumansRibavirinSofosbuvirTreatment OutcomeAntiviral AgentsRibavirinSofosbuvirDirect-acting antiviral agentsGenotype 2Hepatitis CRibavirinSofosbuvirSustained virological response

Identifiers

PMID31177659
PMCPMC12770520

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.